Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunological Variables Associated to ICI Toxicity in Cancer Patients

NCT05429866 is registered in ClinicalTrials.gov with Jules Bordet Institute as lead sponsor.

NCT NCT05429866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05429866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Lead sponsor
Jules Bordet Institute
Phase
Phase 2
Overall status
Unknown status
Start date
September 1, 2022
Completion date
December 1, 2024
Enrollment
441 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, breast cancer, gastrointestinal cancer, head and neck cancer, hepatocellular carcinoma, melanoma, merkel cell carcinoma, mesothelioma, malignant, msi-h colorectal cancer, non small cell lung cancer, non-melanoma skin cancer, renal cell carcinoma, small cell lung cancer